BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Xolair (Omalizumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Xolair (Omalizumab)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06934200-5789@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Xolair (Omalizumab): Phase 2 readout est. (NCT06934200)
DESCRIPTION:Xolair (Omalizumab)\, phase 2.\nStudy: Omalizumab for the Treat
 ment of Food Allergy in Patients With Elevated Total IgE Levels\nEstimated
  primary completion: 15 April 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/omalizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06934200
URL:https://assetmemo.bio/drug/omalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943534-5789@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Xolair (Omalizumab): Phase 2 readout est. (NCT06943534)
DESCRIPTION:Xolair (Omalizumab)\, phase 2.\nStudy: Omalizumab Weight-Based 
 Dosing Efficacy Trial\nEstimated primary completion: 1 May 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/omalizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06943534
URL:https://assetmemo.bio/drug/omalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05332067-5789@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Xolair (Omalizumab): Phase 2 readout est. (NCT05332067)
DESCRIPTION:Xolair (Omalizumab)\, phase 2\, Asthma.\nStudy: Omalizumab Befo
 re Onset of Exacerbations\nEstimated primary completion: 1 January 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/omalizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05332067
URL:https://assetmemo.bio/drug/omalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02570984-5789@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Xolair (Omalizumab): Phase 2 readout est. (NCT02570984)
DESCRIPTION:Xolair (Omalizumab)\, phase 2\, Asthma.\nStudy: Preventing Asth
 ma in High Risk Kids\nEstimated primary completion: 31 January 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/omalizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT02570984
URL:https://assetmemo.bio/drug/omalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816328-5789@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20280524
DTEND;VALUE=DATE:20280525
SUMMARY:Xolair (Omalizumab): Phase 3 readout est. (NCT07816328)
DESCRIPTION:Xolair (Omalizumab)\, phase 3\, Chronic Spontaneous Urticaria.\
 nStudy: Investigation of a Remibrutinib- and Omalizumab-based Treatment Al
 gorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately 
 Controlled by H1-antihistamines Within 24 Weeks\nEstimated primary complet
 ion: 24 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/oma
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07816328
URL:https://assetmemo.bio/drug/omalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845552-5789@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Xolair (Omalizumab): Phase 4 readout est. (NCT07845552)
DESCRIPTION:Xolair (Omalizumab)\, phase 4.\nStudy: Oral Food Challenge Afte
 r One to Two Doses of Omalizumab Treatment for Food Allergy\nEstimated pri
 mary completion: October 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/omalizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07845552
URL:https://assetmemo.bio/drug/omalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059091-5789@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Xolair (Omalizumab): Phase 2 readout est. (NCT07059091)
DESCRIPTION:Xolair (Omalizumab)\, phase 2.\nStudy: Clinical Trial of Omaliz
 umab for Allergen Sensitized and Exposed Individuals With COPD\nEstimated 
 primary completion: January 2031. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/omalizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07059091
URL:https://assetmemo.bio/drug/omalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
